Gene Therapy Reaches XLRS Milestone - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Gene Therapy Reaches XLRS Milestone

Atsena Therapeutics reports positive interim data for XLRS gene therapy

  • May 25, 2026

  • 3 min

Share

Objective:

To evaluate the safety and efficacy of ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS), in a clinical trial.

Key Findings:
  • Structural and functional improvements were observed in treated adults.
  • Foveal schisis closure was confirmed in four of six treated adults in Cohort 4.
  • No serious adverse events were reported across all cohorts.
Interpretation:

Limitations:
  • The study included a small sample size of nine adults and three pediatric patients.
  • Control patients may receive treatment after one year of observation, which could affect outcomes.
Conclusion:

Original Source(s)

Gene Therapy Reaches XLRS Milestone

  • May 25, 2026

Related Content

AI Falls Short on Differential Dx

New PrIME-LLM benchmark shows strong diagnostic accuracy but persistent gaps in clinical reasoning across 21 large language models

Could Red-Light Therapy Change Myopia Care? 

Across 28 trials, pediatric patients receiving therapy had less myopia progression over 12 months, though long-term risks remain under study.

Retinal AI Predicts Neonatal Lung Disease

Retinal scans already performed in the NICU could flag infants at risk for serious lung disease before standard diagnosis